Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | KHK | P50053 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15550246 | 0.79 | CSNK1A1 (0.37) | CSNK1A1CLK4ADORA2AADORA1P2RX3 | |
| SCHEMBL29724139 | 0.78 | CSNK1A1 (0.64) | CSNK1A1CLK4ADORA2AADORA1KHK | |
| SCHEMBL263835 | 0.78 | CSNK1A1 (0.64) | CSNK1A1CLK4ADORA2AADORA1ALDH1A1 | |
| SCHEMBL9043 | 0.78 | CSNK1A1 (0.64) | CSNK1A1CLK4ADORA2AADORA1KHK | |
| SCHEMBL14757551 | 0.75 | ADORA2A (0.51) | CSNK1A1CLK4ADORA2AADORA1KHK | |
| SCHEMBL1579901 | 0.75 | ADORA2A (0.51) | CSNK1A1CLK4ADORA2AADORA1ALDH1A1 | |
| SCHEMBL12765591 | 0.75 | CSNK1A1 (0.46) | CSNK1A1CLK4ADORA2AADORA1KHK | |
| SCHEMBL12726137 | 0.75 | CSNK1A1 (0.46) | CSNK1A1CLK4ADORA2AADORA1KHK | |
| SCHEMBL3554942 | 0.72 | CSNK1A1 (0.40) | CSNK1A1CLK4KHKALDH1A1SMN1; SMN2 | |
| SCHEMBL4064979 | 0.71 | ADORA2A (0.55) | CSNK1A1CLK4ADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | claimed |
| US-20160024051-A1 | SALTS AND SOLID FORMS OF ISOQUINOLINONES AND COMPOSITION COMPRISING AND METHODS OF USING THE SAME | INFINITY PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | claimed |
| EP-2970194-A1 | SALTS AND SOLID FORMS OF ISOQUINOLINONES AND COMPOSITION COMPRISING AND METHODS OF USING THE SAME | Infinity Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014151386-A1 | SALTS AND SOLID FORMS OF ISOQUINOLINONES AND COMPOSITION COMPRISING AND METHODS OF USING THE SAME | INFINITY PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2026-05-21 | — | — | US | disclosed |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | LEUKOS BIOTECH, S.L. (ES) | 2026-02-03 | — | — | US | disclosed |
| EP-4445901-A2 | NEW POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | Leukos Biotech, S.L. (ES) | 2024-10-16 | — | — | EP | disclosed |
| EP-4225753-B1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2024-07-31 | — | — | EP | disclosed |
| US-20240166639-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH, S.L. (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-116981667-A | Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment | 蝎子疗法股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116635390-A | Potent and selective compounds as serotonin 1B receptor modulators | 莱科斯生物技术公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2012146666-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2012083122-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2010042337-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR3B, HTR1B, HTR1A | CSNK1A1 1540/4885CLK4 3848/4885ADORA2A 118/4885 |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | HTR3B, HTR1A, HTR1B | CSNK1A1 1502/4885CLK4 4302/4885ADORA2A 101/4885 |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | CSNK1A1 113/4885CLK4 1786/4885ADORA2A 2497/4885 |
| US-20240166639-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR1B, HTR1A, HTR3B | CSNK1A1 3118/4885CLK4 4855/4885ADORA2A 64/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | CSNK1A1 255/4885CLK4 816/4885ADORA2A 1341/4885 |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | CSNK1A1 348/4885CLK4 481/4885ADORA2A 1298/4885 |
| US-20160024051-A1 | SALTS AND SOLID FORMS OF ISOQUINOLINONES AND COMPOSITION COMPRISING AND METHODS OF USING THE SAME | PIK3CA, PIK3CD, JAK2 | CSNK1A1 45/4885CLK4 280/4885ADORA2A 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.